CAPLYTA — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson CAPLYTA — Sales to customers (Note 9) increased by 13.7% to $480.00M in Q3 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ2 2024
Last reportedQ3 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market demand and successful commercial execution for the product, while a decrease may signal market saturation, increased competition, or loss of patent exclusivity.
Detailed definition
This metric represents the total net revenue generated from the sale of the specific pharmaceutical product line to exte...
Peer comparison
Comparable to product-specific revenue disclosures provided by other large-cap pharmaceutical companies for their key growth drivers.
Metric ID:
jnj_segment_caplyta_sales_to_customers_note_9Historical Data
4 periods
| Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|
| Value | $0.00 | $0.00 | $422.00M | $480.00M |
| QoQ Change | — | — | — | +13.7% |
Range$0.00 – $480.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's caplyta — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported caplyta — sales to customers (note 9) of $480.00M in Q3 2025.
- What does caplyta — sales to customers (note 9) mean?
- The total revenue earned from selling this specific product to customers.